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PREVALENS BAGI POSITIF SEROLOGI DENGGI DI KALANGAN PENDERMA 
DARAH DI HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRAK 
 
Pendahuluan 
 
Unit perubatan transfusi bertanggung jawab untuk menyediakan bekalan darah yang selamat 
kepada pesakit. Kebelakangan ini, terdapat banyak penyakit yang mula menular dan semakin 
meningkat dalam populasi kita, yang menjadikan tugas Unit Perubatan Transfusi semakin 
mencabar. Sebagai contoh, penyakit denggi kini dilaporkan semakin meningkat dan menjadi 
ancaman di negara kita. Dalam tahun 2014, Kelantan dilaporkan sebagai sebagai 
penyumbang utama peningkatan kes denggi di Malaysia, terutamanya di daerah Kota Bharu. 
Penyakit denggi ini boleh terjadi tanpa tanda- tanda ataupun subklinikal. Oleh itu tujuan 
kajian ini dijalankan adalah untuk menentukan prevalens serologi positif bagi penyakit 
denggi di kalangan penderma darah yang sihat. 
 
Metodologi 
 
Kajian keratan rentas ini telah dijalankan dari Mac 2015 hingga February 2016 di Hospital 
Universiti Sains Malaysia (HUSM), Kubang Kerian. Sebanyak seratus dua puluh lapan (128) 
sampel darah telah diperolehi daripada penderma darah yang menderma darah di Unit 
Perubatan Transfusi HUSM dan program pendermaan darah bergerak. Sampel darah tersebut 
telah dijalankan ujian untuk mengenal pasti antigen NS1, dan antibodi IgM dan IgG bagi 
virus denggi dengan menggunakan kaedah ‘immunochromatography (rapid test)’. 
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Hasil Kajian 
 
Hasil daripada kajian ini, didapati satu sampel (0.8%) daripada 128 sampel diuji positif 
untuk antibodi IgM bagi virus denggi, tetapi keputusan untuk ujian antigen NS1 dan antibodi 
IgG bagi virus denggi adalah negatif. Untuk antigen NS1 dan antibodi IgG bagi virus denggi, 
semua sampel daripada 128 sampel (100%) didapati negatif. Daripada kajian ini juga 
didapati tiada perkaitan yang signifikan di antara faktor- faktor seperti jantina, bangsa dan 
jenis penderma dengan serologi positif bagi antibody IgM untuk virus denggi. 
 
Kesimpulan 
 
Kajian ini menunjukkan bahawa terdapat serologi denggi yang positif di kalangan penderma 
darah yang sihat. Walaupun masih belum dapat dipastikan sama ada terdapat demam denggi 
yang berjangkit melalui pemindahan darah di Malaysia, namun hasil kajian ini menimbulkan 
persoalan sama ada penyakit denggi boleh menjadi ancaman kepada bekalan darah yang 
selamat. Oleh itu, kajian yang berskala besar dan lebih komprehensif dengan ujian 
pengesahan seperti ujian isolasi virus, ujian asid nukleik, dan ujian molekular bagi virus 
denggi perlu dijalankan bagi menentukan risiko penyebaran penyakit denggi secara 
pemindahan darah. 
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PREVALENCE OF POSITIVE DENGUE SEROLOGY AMONG THE BLOOD 
DONORS IN HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
Introduction 
 
Blood bank has important duty to provide safe blood to the patients. As many infections 
have emerging and re-emerging in our populations, the duty of blood bank has become 
tougher. For example, dengue infection has become a serious threat to our country recently. 
In 2014, Kelantan has become one of the main contributors to the increase number of dengue 
cases in Malaysia, especially in Kota Bharu. Dengue infection can be subclinical or 
asymptomatic. Therefore, the aim of our study was to determine the prevalence of positive 
dengue serology among the asymptomatic blood donors. 
 
Methodology 
 
A cross-sectional study was conducted starting from March 2015 till February 2016 in 
Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian. Hundred and twenty-eight 
samples were collected from blood donors who donated blood at blood bank and mobile 
blood donation programs. The samples were tested for dengue NS1 antigen, IgM, and IgG 
using immunochromatography method (rapid test).  
 
Results 
 
From this study, there was one sample (0.8%) out of 128 samples was positive for dengue 
IgM antibody. However the sample was negative for dengue IgG antibody and NS1 antigen. 
 
 
xiv 
For dengue IgG antibody and NS1 antigen, all of 128 samples (100%) were negative. There 
were no significant association between gender, age, race and type of donors with positive 
dengue IgM antibody. 
 
Conclusion 
 
This study showed that dengue serology can be positive in asymptomatic donor. Although it 
still cannot be confirmed if any dengue transmission by blood transfusion in Malaysia, but 
these results suggest that dengue can be a possible threat to the blood supply.  However, 
large scale study, supported by confirmatory test like viral isolation test, nucleic acid testing 
or molecular test should be conducted to determine the risk of transfusion- related dengue 
infection. 
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Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
2 
1.0 GENERAL INTRODUCTION 
 
Blood transfusions can be a life-saving treatment but it is not without the risks. The possible 
complications of blood transfusion can be divided into infectious and non-infectious 
complications. Therefore, procedures and protocols to ensure the safety of the blood and 
blood products have become stringent to ensure the benefits to the patients, and to reduce the 
risks, especially in ill-patients. 
 
When the blood transfusion was first introduced, transfusion- transmitted viral infections 
such as Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) 
were high in prevalence. However after the introduction of the serological screening of these 
viruses for blood and blood products, the prevalences for these infections were significantly 
reduced. But, with the emerging and re-emerging diseases that spreading in our population, 
there is a need to assess the risks of transfusion- transmission of these diseases and the 
suitable methods for screening. The American Association of Blood Banks (AABB)‟s 
Transfusion Transmitted Diseases committee has identified 69 infectious diseases that were 
potentially to be transfusion- transmitted infections in the United States and Canada. Among 
them, Babesia, dengue virus, and the prion responsible for variant Creutzfeldt-Jakob disease 
represent high risk agents (Trimble et al., 2010). 
 
The current concern was dengue fever had become serious outbreaks in Malaysia with the 
number of dengue deaths were increasing year by year. Kelantan also had serious outbreaks 
in 2014 with 14,456 cases with 17 dengue deaths were reported compared to 1,427 cases 
with 2 dengue deaths in 2013. Among that, majority of the cases were reported in Kota 
Bharu (MOH, 2015b). In a study reviewing the dengue fever trend in Kota Bharu during the 
years 1998- 2003, they found that the highest percentage of cases were in the age group of 
15 to 29 years old, which accounts for 40.1% of cases (Hussin et al., 2005).  
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As generally known, dengue infection is a mosquito-borne disease, namely Aedes species 
(especially Ae.aegypti, Ae.albopictus and Ae polynesiensis) (McBride and Bielefeldt-
Ohmann, 2000). However other modes of transmission have been reported. Dengue virus 
(DENV) can be transmitted from mother to fetus in utero or to infants at parturition or also 
known as perinatal transmission (Tan et al., 2008; Pouliot et al., 2010). It is even more 
alarming since a few cases of dengue infections after receipt of blood and blood products had 
been reported. The blood products that were used in these cases included platelet 
concentrates, fresh frozen plasma and packed red cell from viraemic asymptomatic blood 
donors (Chuang et al., 2008; Tambyah et al., 2008).
 
Other than transfusion- related, dengue 
infections related to organ/ tissue transplant and after occupational exposure in a health care 
setting also have been reported (Chuang et al., 2008; Tambyah et al., 2008; Wilder-Smith et 
al., 2009). Risk is high in endemic areas as most DENV infections are asymptomatic and the 
viraemia is high titered, long lasting and detectable among asymptomatic individuals. The 
donor infectivity rate was estimated to be nearly 1 in 1000 donation  (Mohammed et al., 
2008; Seed et al., 2009).  
 
The person infected with DENV can be either symptomatic or asymptomatic. It is estimated 
that 50-80% of DENV infected cases are asymptomatic, leading to potential transfusion- 
transmitted cases of DENV from infected donors (Mohammed et al., 2008; Munoz-Jordán et 
al., 2009). It is problematic if the asymptomatic person comes to donate blood because he 
still can transmit the virus into the recipient since he is still in viraemic state. Exclusion of 
donors in endemic areas during the high- incidence dengue season or during an outbreak is 
not feasible since the entire population is at risk of DENV infection, and the need for blood 
components is typically high during outbreaks and outbreaks can be long lasting (Tomashek 
and Margolis, 2011). 
 
Therefore, the aim of this study was to address this issue and to determine the prevalence of 
positive dengue serology in the healthy blood donor population. 
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2.1 Blood donation and transfusion  
 
2.1.1 Blood donation process 
 
The blood donation process is started with blood donor procurement. Blood donation should 
be procured from voluntary non renumerated blood donors. Blood donor recruitment 
activities should be active and continuous to ensure adequate blood supply (PDN, 2008). 
However, to ensure the safety of blood donors and blood recipients, selection of blood 
donors should be guided by strict donor criteria. The criteria can vary among the blood bank 
centres.  
 
The blood donors who donate the blood should be healthy, free of diseases or medical 
illness, and also do not have any risk factors for HIV, HBV, HCV, and Syphilis. The criteria 
for donor acceptance includes age (between 18 to 65 years old), weight (more than 45 kg), in 
good health with no medical history that can harm themselves or the blood recipient 
(including bleeding disorders, medications, or recent illness), adequate rest (sleep more than 
5 hours), haemoglobin level between 13.5 to 18.0 g/dL for male and 12.5 to 18.0 g/dLfor 
female, and appropriate blood donation interval (more than 8 weeks for whole blood donor, 
and more than two weeks for apheresis donor) (NBC, 2016).  
 
All candidates for blood donors should undergo pre-donation questionnaire and counselling 
by trained blood bank staffs (include doctors and nurses). The counselling process is to 
assess the donor‟s health and to explain regarding the process of blood donation. During this 
process, the donors are educated and emphasized regarding the importance of disclosing any 
risk factors to ensure blood safety. This is then proceeded by screening the donors for any 
risks, either medical or behavioural risks, that can cause harm from the blood donation, 
either to the recipient later, or even to the donor himself. Usually this is done by screening 
the donors using a standard questionnaires. The content of the questionnaires may vary from 
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a blood bank centres to one another, especially in different countries. This is due to different 
prevalence of adverse reactions, cultural influences and other factors in one centre may differ 
from another centre (Karp and King, 2010). 
 
After the counselling, the consent should be obtained. These candidates should be deferred if 
they are having conditions as mentioned in the donor deferral criteria. The detailed 
Guidelines for Donor Deferral are as in Appendix 1 (NBC, 2016).  
 
All blood donors should be checked for blood pressure, haemoglobin level and blood group. 
Once the donors are qualified, the donors‟ identity should be verified before blood is 
collected, and ensured that all the labels of the blood bags and specimen bottles for infection 
screening are correct. The blood collection starts with venepuncture, which should follow 
strict Standard Operating Procedure (SOP) such as cleaning at the venepuncture site to 
reduce the risk of contamination during blood collection. For a successful blood collection, it 
requires successful venepuncture and proper mixing of blood. The ideal duration of bleeding 
process should not exceed 10 minutes (NBC, 2016). Post donation, the donors should have 
adequate rest before discharge. The donors also should be advised for adequate fluid intake 
after being discharged. 
 
The blood that has been collected must have ABO and Rhesus blood grouping to be done, as 
well as screening for transfusion- transmitted infection. Other than that, they  must be tested 
for infectious screening. In Malaysia, it includes HIV, Hepatitis B Virus (HBV), Hepatitis C 
Virus (HCV), and Syphilis, as per recommendation by World Health Organization for blood 
safety (WHO, 2016a). Any blood which is tested positive will be discarded to prevent 
transfusion transmitted diseases. The implicated donor will be called for further testing and 
confirmation. 
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2.1.2 Demographic Characteristics of Blood Donors 
 
The blood donors can be grouped into voluntary non- remunerated blood donors, directed or 
replacement blood donors and paid blood donors. As much as possible, voluntary non- 
remunerated blood donors are preferred to ensure safe and reliable blood supply (WHO, 
2016a). Many studies have shown that the prevalence of transfusion transmitted infection is 
the lowest in this group (Zou et al., 2012).  
 
Female gender has been reported to have slightly higher proportion (~50%) compared to 
male gender among the new blood donors. However, the successful blood donation and 
repeat donations were more likely contributed by male gender (Zou et al., 2012; Lattimore et 
al., 2015). Repeat donors, who donated more than 1 time, accounted for majority (>70%) of 
blood donors, compared to first time donors.  The mean number of donation was about 2 
donations (Zou et al., 2012; Lattimore et al., 2015).  
 
Regarding the infectious diseases, the prevalence of positive serology is persistently higher 
among first time blood donors compared to repeat donors. This is partly contributed by the 
facts that repeat donors are aware of self-deferral and the benefits of donor testing and 
deferrals of donors with previous confirmed positive serology of the tested infectious 
diseases. Among the positive serology donors, the male gender was more prominent 
compared to female gender (Zou et al., 2012). 
 
2.1.3 Blood Component Processing 
 
Blood that is collected can be either as whole blood or by apheresis. Apheresis is a collection 
of specific blood component either plasma or platelets. After collection, the blood bags 
should be kept at appropriate temperature to maintain the quality. For component preparation 
from whole blood, the blood bag will be centrifuged at different speed and temperature, 
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depending on the types of component to be prepared. From one whole blood, the 
components that can be prepared include packed red cells and platelet concentrates, or 
packed cells and fresh frozen plasma, cryoprecipitate and cryosupernatant. All products must 
be adequately labelled based on the SOP; consist of the bag number, date of collection, ABO 
and Rhesus blood group, name of the component, and date of expiry (NBC, 2016).  
 
2.1.4 Blood Transfusion Process 
 
The decision for blood transfusion should be justified to benefit the patient and to avoid 
unnecessary transfusion. Unnecessary blood transfusion will cause inappropriately exposed 
the patient to infectious and non-infectious risks of blood transfusion. The patient should be 
explained regarding the blood transfusion, including the benefits, risks and alternatives, and 
consent should be obtained before the procedure (Farrugia, 2009; Vamvakas and Blajchman, 
2009).  
 
The request for blood transfusion should be accompanied by request form and sample, which 
are taken according to the SOP, to avoid unnecessary errors. Pre transfusion testing will be 
done by the blood bank laboratory which includes ABO and Rhesus blood grouping, and 
antibody screening. If the antibody screening test is positive, the test will be followed by 
antibody identification test. Upon request, the cross matching between the patient‟s blood 
and the donor‟s blood will be done. Only compatible blood or with specific requirement if 
any is supplied to the patient (NBC, 2016).  
 
Before administering the blood to the patient, identity check should be carried out and verify 
the correct patient with the compatibility label by the blood bank. After identifying the 
correct patient and the correct blood, the transfusion can be started. The patient should be 
monitored closely including vital signs and any adverse reactions of blood transfusion. If any 
adverse reactions occur, appropriate action and resuscitation of the patient should be taken. 
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All adverse reactions should be reported to the blood bank and should be investigated. In all 
steps of blood transfusion, adequate and appropriate documentation should comply 
according to the SOP of the respective blood transfusion unit (NBC, 2016). 
 
2.2 Blood safety 
 
Blood safety is the main concern in the modern blood banking. It encompasses actions aimed 
at ensuring that everyone has access to blood and blood products that are as safe as possible, 
available at reasonable cost.  At the same time, it is adequate to meet the needs of patients, 
only transfuse when necessary, and provide as part of a sustainable blood program within the 
existing health care system (WHO, 2016a). The threats in blood safety can be infectious and 
non- infectious agents. As many emerging and re-emerging infections have increased, more 
stringent measures are required to ensure the safety of blood and blood components supplied 
to the patients. However this task has become tougher with globalisation of blood and blood 
products. This is especially true for plasma fractionation products as they were made global 
compared to red cells which usually are used locally (Farrugia, 2009).  
 
2.2.1 Non-Infectious Risks 
 
With the effectiveness of screening methods of blood and blood components, the major 
cause of allogeneic blood transfusion complication and mortality is contributed by non-
infectious risk. In United States (US), the leading causes of transfusion related mortality are 
currently included transfusion-related acute lung injury (TRALI) and hemolytic transfusion 
reactions (HTRs) (Vamvakas and Blajchman, 2009). The incidence of blood transfusion–
related deaths in US and United Kingdom (UK) are as in Figure 2.1. 
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Figure 2.1. Causes of allogeneic blood transfusion–related deaths as a percent-age of all 
deaths reported to Severe Hazards of Transfusion (SHOT) (1996-2007) or the Food and 
Drug Administration (FDA) (2005-2007). (Adapted from (Vamvakas and Blajchman, 
2009)). 
 
The other potentially fatal complications of blood transfusion includes transfusion- 
associated graft-versus-host disease (TA-GVHD), transfusion associated circulatory 
overload (TACO), anaphylaxis, and post transfusion purpura (PTP). The definition of these 
complications is as below in Table 2.1. 
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Table 2.1. Potentially fatal non-infectious complications of allogeneic blood transfusion  
 
 
Complication Definition Mechanism 
Transfusion-
related acute lung 
injury (TRALI) 
New acute lung injury (ALI) 
occurring within 6 hours after a 
transfusion, with a clear 
temporal relationship to the 
transfusion, in patients without 
risk factors for ALI other than 
transfusion* 
Donor anti-WBC antibodies 
attacking the recipient‟s WBCs 
in the microcirculature of the 
lungs 
“Two-hit” hypothesis implicating 
biologic response modifiers 
accumulating in supernatant 
plasma during storage† 
 
Hemolytic 
transfusion 
reactions (HTRs) 
Immune destruction of the 
transfused donor RBCs which 
are attacked by the recipient‟s: 
“naturally occurring” 
antibodies to the A or B 
antigens of the ABO blood 
group system, and/or 
alloantibodies to other RBC 
antigens produced following 
immunization through a 
previous transfusion or 
pregnancy 
Acute HTR: Destruction of 
“incompatible” donor RBCs 
intravascularly or extravascularly 
(in the liver and/or spleen) by 
preexisting circulating antibody 
within 24 hours of a transfusion‡ 
 
Delayed HTR: Destruction of 
“compatible” donor RBCs 7-10 
days after a transfusion, 
following an anamnestic immune 
response to a donor RBC antigen 
to which the recipient has been 
alloimmunized by a previous 
transfusion or pregnancy 
 
Transfusion-
associated graft-
versus-host 
disease 
(TA-GVHD) 
Immune attack against the 
recipient‟s tissues and organs 
by donor lymphocytes which 
engraft, proliferate, and mount 
an immune assault against the 
recipient 
Donor lymphocytes not cleared by: 
immunocompromised patients 
and patients who receive 
components from donors (eg, 
relatives) with whom they 
partially share HLA haplotypes 
survive and engraft in the 
recipient 
 
Transfusion-
associated 
circulatory 
overload (TACO) 
Acute pulmonary edema 
secondary to congestive heart 
failure precipitated by 
transfusion of a volume of 
blood greater than what the 
recipient‟s circulatory system 
can tolerate 
Usually rapid infusion or massive 
transfusion of blood in patients 
with diminished cardiac reserve, 
chronic anemia, infants, and the 
elderly, although no patient is 
immune 
 
 
Anaphylaxis Anaphylactic response of a 
presensitized patient to various 
proteins contained in donor 
plasma 
Often, donor IgA infused into an 
IgA-deficient recipient with 
preexisting circulating anti-IgA  
triggers anaphylaxis 
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Table 2.1 Continued 
   
Posttransfusion purpura 
(PTP) 
Sudden, severe 
thrombocytopenia 
occurring 7-10 days after 
transfusion in a patient 
previously alloimmunized 
(by pregnancy or 
transfusion) to a platelet-
specific antigen 
Production of potent 
alloantibody to a platelet-
specific antigen through an 
anamnestic immune 
response that follows 
reexposure to the antigen 
on the donor‟s platelets. 
Paradoxically, the antibody 
destroys the recipient‟s 
own (antigen-negative) 
platelets as well 
 
*A category of possible TRALI encompasses cases in which patients have other risk factors 
for ALI temporally related to the transfusion. 
†See text in the “TRALI” subsection. 
‡Hemolysis often starts early during the transfusion in the case of an ABO-incompatible 
transfusion. (Adapted from (Vamvakas and Blajchman, 2009)) 
 
Other complications of blood transfusion include febrile non-hemolytic transfusion reaction 
and allergic reaction. These are usually non-fatal, and can be prevented by giving 
premedication to the recipient prior administering the blood or blood products. 
 
2.2.2 Infectious Risks 
 
An emerging infection is the infection that shows increasing trend within two decades or 
threatens to increase in the future (Allain et al., 2009; Trimble et al., 2010). This infection 
can become transfusion risks as more people in the population are exposed to the infectious 
agent especially during endemic and epidemic period. Among the transfusion risks, there are 
the risks that are known and unknown (Trimble et al., 2010).  
 
The known transfusion risks include Hepatitis B, Hepatitis C, HIV and Syphilis. Over the 
past 30 years, the world has seen that there was marked decreased in the incidence of post- 
transfusion by these viruses, currently about less than 1 in 1 million transfusion, due to 
effective screening for these viruses. However, even with the known transfusion risks which 
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have established and effective methods of screening, there are still problems in detecting the 
infection during the window period (Trimble et al., 2010).  
 
 
Figure 2.2. Reduction in the risk of transmission of the 4 most frequently transmitted, 
potentially fatal, transfusion-acquired infections in the US since the mid-1980s. (Adapted 
from (Vamvakas and Blajchman, 2009). 
 
Among the unknown risks, there are pathogens which are predictable to be a transfusion risk, 
such as West Nile Virus (WNV) in US and DENV in Puerto Rico (Klein, 2010).  The 
AABB‟s Transfusion Transmitted Diseases committee has identified significant numbers of 
infectious diseases that were potentially to be transmitted by transfusion in the United States 
and Canada, including Babesia, dengue virus, and the prion responsible for variant 
Creutzfeldt-Jakob disease is considered as high risk agents (Allain et al., 2009; Trimble et 
al., 2010). However, these risks may differ from one country to another based on many 
factors, for example the geography, socioeconomic status and quality of healthcare system.  
Therefore, evaluation of the transfusion risks related to these possibly new threat for each 
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country should be done periodically by proactive strategies and recipient surveillance 
(Trimble et al., 2010).  
 
2.2.3 Strategies for blood safety 
 
The steps in ensuring blood safety include donor selection, laboratory testing for infective 
agents, and aseptic technique as well as on proper storage. Many strategies are developed to 
ensure blood safety, which include promoting voluntary non-remunerated donors, supporting 
repeated donations, emphasizing on self-deferral, adhering to strict donor screening criteria, 
and sensitive and specific serological tests for screening for viral markers on donated blood 
(Nafishah et al., 2014). 
 
In many countries, questionnaires are used as screening tools during donor selection process. 
Deferring the candidate donors based on risks factors of these transmissible infections can 
prevent collecting the contaminated blood. This is not only can save time and resources from 
testing the contaminated unit but also reduced the risks of exposure to the laboratory 
personnel and possible transfusion error. However, it has low sensitivity and specificity that 
can lead to deferring otherwise healthy donors (Epstein, 2010; Klein, 2010). In a study 
conducted in Canada showed that the face to face interview during screening for high risk 
behaviour before blood donation did not change the incidence rate of HIV or HCV among 
first time blood donors (Zou et al., 2012).A small proportion of the blood donors, especially 
the young and first time donors, they tend to hide the risk factors possible due to several 
reasons. In a study by Vahidnia et a.l, 2016, they found that there were a proportion of 
donors, thought that current donor health screening questionnaires and deferral policies were 
unfair in which their reasons included ineligibility of “some groups of people”, travel 
restrictions, or a long questionnaire for repeat donors (Vahidnia et al., 2016). These reasons 
may lead to non-disclosure of deferrable risk factors. 
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From previous studies, demographic characteristics can give prediction regarding which 
group are more likely to have the risk factors. In a study regarding donor testing and and risk 
in US allogenic donations, younger age group, male gender, and first time blood donors are 
potential factors to predict the risks for transfusion-related infections, especially HIV, 
Hepatitis B and C viruses, Syphilis, HTLV and West Nile Virus (Zou et al., 2012; Custer et 
al., 2015). Similar findings were also observed in a study conducted in National Blood 
Centre, Kuala Lumpur (Nafishah et al., 2014). 
 
The laboratory testing for infectious diseases are very crucial and highly cost effective, even 
though their performances are largely depending on the methods used and their costs. Other 
than to detect these diseases, they also serve as a platform for donor education, treatment, 
and preventive measures as the positively tested donors are managed and treated accordingly 
and they are deferred either temporarily or permanently based on type of the diseases 
(Epstein, 2010). However, to screen for all potential transfusion risks is impossible and not 
cost effective. Therefore only selected infectious diseases are tested; namely Hepatitis B, 
Hepatitis C, HIV and Syphilis in many part of the world. Screening for these infectious 
agents is also highlighted as basic requirement for blood bank by WHO (WHO, 2016a). The 
testing methods have been improved remarkably with the introduction of nucleic acid testing 
(NAT) together with serological testing, in which these test shorten the detectable period to 
days or weeks. However, they still cannot completely eradicate the possibility of 
transmission by these infectious agents during window period (Klein, 2010; O'Brien et al., 
2012). Despite the introduction of nucleic acid testing (NAT), the residual risks of 
transfusion-related infection for each agent is estimated to be 1 in 300 000 to 1 million units 
(Zou et al., 2012; Custer et al., 2015). This is because that there is still a period of time that 
the viral markers for these agents are remain undetectable probably due to low titre 
eventhough it has been markedly reduced by this test (Zou et al., 2012). 
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2.2.4 Dengue threat to the blood supply 
 
Dengue infection is an endemic in tropical and subtropical countries, including Malaysia. 
Dengue infection has become a serious threat to the public health as the reported cases have 
been increased in trends. The nature of dengue infection is also variable, from asymptomatic 
infection, mild febrile illness to severe illness complicated by shock and even death 
(McBride and Bielefeldt-Ohmann, 2000).  
 
Previously, dengue infection is only known as vector-borne infection, transmitted from 
human to human by mosquitoes, namely Aedes sp. However, there was increased awareness 
of the possibility of other mode transmission of dengue infection. The more serious concern 
is the healthcare-associated transmission. There were a few reported cases of dengue 
infection transmitted by percutaneous, mucocutaneous, blood transfusion, bone marrow 
transplant and renal transplant (Wilder-Smith et al., 2009). For example, there was a case 
reported in Hong Kong in 2002 of transfusion associated dengue infection in a lady who 
developed febrile illness after receiving blood contaminated by dengue virus (Chuang et al., 
2008). There was also another case reported in Singapore in 2007 of a donor who reported to 
develop febrile illness which later confirmed to dengue infection a days after whole blood 
donation. The three recipients who received his blood and blood products (packed red cell, 
fresh frozen plasma and platelets) were all positive for dengue serology (Tambyah et al., 
2008). 
 
A few studies were also conducted in endemic area to identify the risk of transfusion-
associated dengue infection. In a study in Puerto Rico, they found that as high as  59% of 
donors were positive for anti-DENV IgG and 16 (2%) were positive for anti-DENV IgM 
antibodies (Rodríguez Rodríguez et al., 2009). In different studies, the results showed there 
were significant rate of viraemia (about 0.07%) in asymptomatic blood donors in endemic or 
epidemic areas (Rodríguez Rodríguez et al., 2009; Seed et al., 2009; Teo et al., 2009). These 
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findings suggest that there is presence of risk to collect the blood from viraemic donor during 
asymptomatic or subclinical dengue infection. 
 
The impact of dengue infection towards blood donors and blood supply is also significant. In 
some countries, the donor who has been infected with dengue is deferred up to 6 months. 
This will cause a loss of potential blood donation frequency as many as 2- 3 times of whole 
blood donation, or 12- 13 times of apheresis donation in regular blood donors (Teo et al., 
2009). The table 2.2 illustrates the dengue and deferral period in selected countries. 
 
Table 2.2. Dengue and donor deferral. 
 
Country Donor deferral measures for dengue 
Singapore* 6 months deferral for history of dengue infection 
3 weeks deferral for history of fever 
No travel-related deferral for dengue 
 
Hong Kong* 6 months deferral for history of dengue infection 
2 weeks deferral for history of fever 
No travel-related deferral for dengue 
 
Sri Lanka* No specific deferral for history of dengue infection 
2 weeks deferral for history of fever 
No travel-related deferral for dengue 
 
Australia† 4 weeks deferral for history of dengue infection 
No travel-related deferral for dengue 
 
New Zealand‡ 4 weeks deferral for history of dengue infection 
No travel-related deferral for dengue 
 
UK‡ 2 weeks deferral for history of dengue infection 
No travel-related deferral for dengue 
 
United States‡ 4 weeks deferral for history of dengue infection 
No travel-related deferral for dengue 
*Endemic for dengue. 
†Non-endemic except parts of Northern Australia. 
‡Non-endemic. 
(Adapted (Teo et al., 2009) 
 
In Malaysia, previously the deferral period for a person who have dengue infection is 4- 6 
weeks after recovery (PDN, 2008). However, due to increasing evidence of transfusion 
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associated dengue infection and recent outbreaks, the deferral period has been extended to 6 
months after full recovery, and 14 days after acute febrile illness (NBC, 2016).  
 
The requests for blood and blood products, especially platelets are also increased during 
dengue outbreaks. Combination of donor deferrals and increased requests for blood and 
blood products will affect the blood bank services. Therefore, judicious use of blood and 
blood products are strictly emphasized to avoid unnecessary transfusion and subsequently 
unnecessary risks (Teo et al., 2009; Tomashek and Margolis, 2011). 
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2.3 Dengue  
 
2.3.1 Dengue Virus 
 
Dengue fever is caused by DENV, which belongs to family Flaviviridae, genus Flavivirus. 
DENV is a spherical, lipid-enveloped virus which contains a positive strand RNA genome 
that codes for three structural proteins, which are capsid, membrane and envelope. It also 
encodes for seven non-structural (NS) proteins namely the NS1, NS2a, NS2b, NS3, NS4a, 
NS4b, NS5 (Chawla et al., 2014). DENV have 4 known serotypes, which are DENV-1, 
DENV-2, DENV-3, and DENV-4. It is a vector-borne disease, which is transmitted by 
female Aedes mosquitoes of the subgenus Stegomyia (especially Ae. aegypti, Ae. albopictus 
and Ae. polynesiensis) as the primary mosquito vectors, with human as its primary hosts 
(McBride and Bielefeldt-Ohmann, 2000).  
 
 
Figure 2.3. Stages in the transmission of dengue fever from individual to individual. A 
period of between 13 and 31 days is estimated to elapse between successive cases in an 
epidemic. (Adapted from (McBride and Bielefeldt-Ohmann, 2000) 
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The female Ae. aegypti must bite an infected human during the viraemic phase of the illness 
for the transmission to occur. The viraemic phase is generally last 4 to 5 days but may last up 
to 12 days. The extrinsic incubation period refers to the time required from when a viraemic 
human is bitten to when the mosquito itself becomes infective. This period is about 8 to 12 
days. Figure 2.3 illustrates the time periods in the cycle of dengue virus transmission 
(McBride and Bielefeldt-Ohmann, 2000). 
 
Ingestion of the infected blood by the mosquitoes causes the infection of the epithelial lining 
of the midgut in the mosquitoes. The virus escapes from the midgut epithelium into the 
haemocele before infecting the salivary gland and being secreted in the saliva. The genital 
tract can also be infected and the virus can enter the fully developed egg at the time of 
oviposition (McBride and Bielefeldt-Ohmann, 2000). 
 
The feeding behaviour of the mosquito is characterized by easily interrupted feeding and 
repeated probing of one or several hosts. Therefore the persistence of dengue virus depends 
on the development of high viral titres in hosts to ensure transmission in mosquitoes 
(McBride and Bielefeldt-Ohmann, 2000). 
 
2.3.2 Epidemiology 
 
WHO recently estimated that there might be 50-100 million dengue infections every year 
worldwide (Chawla et al., 2014). However some reviews estimated up to 390 million dengue 
infections per year including asymptomatic individuals with 96 million with clinical 
manifestations (Bhatt et al., 2013). Dengue has been endemics in tropical and subtropical 
countries, especially in the urban area. The Asian countries is estimated to bear about 70% of 
dengue burden (Wilson and Chen, 2015). However, due to few factors such as global 
travelling, urbanization and climate changes, dengue cases have spread worldwide and 
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become a global health problem. Increased dengue cases have been reported in non-endemic 
area such as in Middle East (Wilson and Chen, 2015).  
 
 
Figure 2.4. Cartogram of the annual number of infections for all ages as a proportion of 
national or subnational (China) geographical area. (Adapted from (Bhatt et al., 2013). 
 
Before 1970, less than 10 countries were reported to have severe dengue epidemics. 
However, the number has risen to more than 100 countries in the WHO regions; including 
America, Africa, South-East Asia, Eastern Mediterranean, and Western Pacific. Among 
these regions, America, South-East Asia and Western Pacific were most seriously affected 
(Pawar and Patravale, 2015). 
 
Dengue has been endemic in Malaysia since the 1970s, but the incidence has also been 
increased in recent decades. It has been studied that the incident rate (IR) in Malaysia 
increased from 32 cases per 100,000 population in 2000 to 361 cases in 2014, though a 
temporary reverse trend was observed in 2011 and 2012 (Hii et al., 2016). The dengue was 
affecting mainly in the age group of 15 and above in which IR is higher. The urban areas 
were documented to report most of the dengue cases (70%–80%) where the factors such as 
high density population and rapid development made dengue to be more transmissible. The 
dengue case fatality rate was reduced from 0.6% in year 2000 to 0.2% in year 2014, down to 
the national target rate. Most of the dengue death was observed to be higher in the age group 
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of 15 years and above, corresponding to the high incidence in this age group, and the highest 
rate was observed in 2004 (MOH, 2015a). 
 
In Malaysia, exposure to dengue virus is high. It is demonstrated by a study conducted in 
West Malaysia involving 1000 subjects found that the rate of Immunoglobulin G (IgG) 
seropositivity is >90% (Azami et al., 2011). In this study, they also found out that age was a 
significant risk factor in dengue, in which the seroprevalence was increased with every 10 
year increment. However seroprevalence of dengue was similar among ethnic groups and 
between genders. There was also not much different among urban and rural residents, 
suggesting that dengue was widespread across the country (Azami et al., 2011). In another 
study conducted in Barbados, a country where dengue is also an endemic, similar findings 
were observed. The findings showed that by the age of 18, over 80% of the studied 
population had seroconverted and by 25 years, more than 90% of the study population was 
positive for the IgG antibody to one or more dengue serotypes. Other than that, this study 
also found out that dengue was three to four times more likely to be a secondary than a 
primary infection in country where dengue was an endemic. These findings indicate that this 
population was immune to only some of the dengue serotypes. Therefore, further dengue 
infection with different serotypes in partially immune individuals would potentially increase 
the risk of more severe forms of dengue such as DHF in the future (Kumar and Nielsen, 
2015). 
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Figure 2.5. Seroprevalence of dengue at the different study sites in Malaysia. The percentage 
of dengue prevalence at each site is presented as different coloured concentric circles. 
(Adapted from (Tiong et al., 2015)). 
 
2.3.3 Clinical features 
 
As agreed by expert consensus groups of WHO, dengue is described as “one disease entity 
with different clinical presentations and often with unpredictable clinical evolution and 
outcome” (WHO, 2009). Clinically, dengue infection may result in wide spectrum of illness, 
ranging from asymptomatic, mild fever to severe and potentially fatal disease in small 
proportion of patients (Chawla et al., 2014). Most of the dengue infections are 
asymptomatic. In symptomatic patient, majority will present with mild febrile illness, but 
small proportion will developed severe dengue with severe bleeding manifestation, organ 
impairment, and may be complicated with hypovolemic shock due to systemic plasma 
leakage (WHO, 2009; Chawla et al., 2014).  
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Previously, the dengue syndrome can be categorized into undifferentiated fever, classic 
dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) (Chawla 
et al., 2014; Pawar and Patravale, 2015). However, due to its practical limitations in triaging 
the dengue patients, a revised dengue classification which was classified by an expert group 
was developed (WHO, 2009; Guzman et al., 2010).  Figure 2.6 showed the revised dengue 
classification and its criteria. 
 
 
Figure 2.6 Suggested dengue case classification and levels of severity (adapted from(WHO, 
2009)). 
 
In general, it can be divided into 3 phases; febrile, critical and recovery/ resorption phase 
(Figure 2.7) (WHO, 2009; Chawla et al., 2014). In febrile phase, it is commonly manifested 
as fever associated with rash, headache, ocular pain, arthralgia, myalgia, with or without 
mild upper respiratory tract and gastrointestinal symptoms (Guzman et al., 2010; Liew et al., 
2016). However, these symptoms are overlapping with other tropical diseases such as 
measles, typhoid, leptospirosis and influenza. Therefore in this phase, it is difficult to 
differentiate between them. Positive tourniquet test make dengue diagnosis more favourable. 
Mild bleeding manifestations like petechiae and mucosal bleeding (e.g. epistaxis or gum 
